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Table 1. Most common AEs, irrespective of causality (≥20% in either treatment arm) 
AE, n (%) 
Ribociclib (600 mg) plus letrozole (2.5 mg) 
n=334 
Placebo plus letrozole (2.5 mg) 
n=330 
All grades Grade 3 Grade 4 All grades Grade 3 Grade 4 
Neutropenia
a
 257 (76.9) 175 (52.4) 32 (9.6) 19 (5.8) 4 (1.2) 0 
Nausea 178 (53.3) 8 (2.4) 0 101 (30.6) 2 (0.6) 0 
Fatigue 138 (41.3) 9 (2.7) 1 (0.3) 107 (32.4) 3 (0.9) 0 
Diarrhea 128 (38.3) 8 (2.4) 0 81 (24.5) 3 (0.9) 0 
Alopecia 115 (34.4) 0 0 53 (16.1) 0 0 
Vomiting 112 (33.5) 12 (3.6) 0 55 (16.7) 3 (0.9) 0 
Arthralgia 111 (33.2) 2 (0.6) 1 (0.3) 108 (32.7) 4 (1.2) 0 
Leukopenia
b
 110 (32.9) 67 (20.1) 4 (1.2) 15 (4.5) 3 (0.9) 0 
Constipation 93 (27.8) 4 (1.2) 0 71 (21.5) 0 0 
Headache 90 (26.9) 1 (0.3) 0 69 (20.9) 2 (0.6) 0 
Hot flash 82 (24.6) 1 (0.3) 0 84 (25.5) 0 0 
Back pain 81 (24.3) 10 (3.0) 0 67 (20.3) 1 (0.3) 0 
Cough 77 (23.1) 0 0 70 (21.2) 0 0 
Rash
c
 74 (22.2) 5 (1.5) 0 29 (8.8) 0 0 
Anemia
d
 71 (21.3) 6 (1.8) 2 (0.6) 19 (5.8) 4 (1.2) 0 
Decreased 
appetite 
69 (20.7) 5 (1.5) 0 52 (15.8) 1 (0.3) 0 
Abnormal LFTs
e
 67 (20.1) 28 (8.4) 6 (1.8) 21 (6.4) 8 (2.4) 0 
a
Neutropenia includes “neutropenia”, “decreased neutrophil count”, and “granulocytopenia”.  
b
Leukopenia includes “decreased white blood cell count” and “leukopenia”.  
c
Rash includes “rash” and “maculopapular rash”.  
d
Anemia includes “anemia”, “decreased hemoglobin”, and “macrocytic anemia”.  
e
Abnormal LFTs includes “increased alanine aminotransferase”, “increased aspartate 
aminotransferase”, and “increased blood bilirubin”.  
AE, adverse event; LFT, liver function test. 
Data cut-off: January 4, 2017. 
 
Downloaded from https://academic.oup.com/annonc/advance-article-abstract/doi/10.1093/annonc/mdy155/4989216
by Edinburgh University user




Figure 1. CONSORT diagram of patient flow in MONALEESA-2  
 




by Edinburgh University user




Figure 2. Kaplan–Meier graph of investigator-assessed PFS for ribociclib plus letrozole versus 
placebo plus letrozole CI, confidence interval; PFS, progression-free survival. Data cut-off: January 2, 
2017.  
 




by Edinburgh University user




Figure 3. Subgroup analysis of PFS for ribociclib plus letrozole versus placebo plus letrozole AI, 
aromatase inhibitor; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance 
status; ER+, estrogen receptor-positive; HR, hormone receptor; PFS, progression-free survival; PgR+, 
progesterone receptor-positive; TAM, tamoxifen. Data cut-off: January 2, 2017.  
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Figure 4. Kaplan–Meier graph of investigator-assessed OS for ribociclib plus letrozole versus 
placebo plus letrozole CI, confidence interval; NR, not reached; OS, overall survival. Data cut-off: January 
2, 2017.  
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